ReviewNature reviews. Clinical oncology2025
Enhancing immunotherapy with tumour-responsive nanomaterials.
Review in Nature reviews. Clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed.
- Enhancing immunogenic cell death by targeting the GPX4-ZP3 immune checkpoint.Oncoimmunology · 2026Article
- Nanomedicine-based cancer immunotherapy: translational barriers, mechanistic strategies, and future perspectives.Drug delivery · 2026Review
- GSH-responsive nanovaccine triggers immunogenic cell death and potent memory T cell immunity for durable, recurrence-free tumor eradication.Bioactive materials · 2026Article
- Collagen-Binding IL-15 Immunocytokine Armed Oncolytic Adenovirus Establishes a Self-Reinforcing Immunostimulatory Milieu to Potentiate Antitumor Immunity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Tumor Exposomics: A New Paradigm for Individualized Continuous Exposure Monitoring.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Nanoparticulate and Hydrogel Vehicles for Stimuli-Responsive and Sustained Controlled Release of Active Pharmaceutical Ingredients.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Chemically Masked aPD-L1-Sialidase Conjugate for Tumor-Specific Desialylation and Immunotherapy.Angewandte Chemie (International ed. in English) · 2026Article
- Cell Selective STING-Activating Polysaccharide Immunomodulators for Cancer Therapy.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Modular Vaccine Robots for Spatiotemporal Programming of the CD4Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- An inflammation-modulating ferroptotic nanoplatform for immune-compatible cancer therapy.Journal of nanobiotechnology · 2026Article
- Stimuli-responsive nanocarriers for targeted mRNA therapeutics: a paradigm shift in mRNA delivery for biomedical applications.Drug delivery and translational research · 2026Review
- The RNA delivery dilemma-lipid versus polymer nanoparticle platforms.Drug delivery and translational research · 2026Article
- Biomolecular Interfaces in Targeted Nano-Drug Delivery: Molecular Recognition, Signaling Modulation, and Translational Pathways.Biomolecules · 2026Review
- CORE: Cholesterol Altered Lipid Nanoparticles for Splenic Expression of mRNA Payloads.Advanced healthcare materials · 2026Article
- Bridging functional bionanomaterials and the clinic: strategic communication as a translational enabler.Journal of nanobiotechnology · 2026Review
- AND-Logic-Based Dual-Lock Hemicyanine Fluorescence Probe for Accurate Hypoxia Assessment in Tumors.Chemical & biomedical imaging · 2026Article
- Porphyrin oriented bimetallic sonodynamic MOF for enhanced ferroptosis and cGAS-STING pathway mediated antitumor immunotherapy.Journal of nanobiotechnology · 2026Article
- Tumor-Targeted Delivery Therapy Based on PLGA Nanoparticles.Journal of functional biomaterials · 2026Review
- Leveraging the crosstalk between cGAS-STING and pyroptosis by nanomedicine to enhance antitumor immunity.Journal of nanobiotechnology · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The targeted delivery of immunotherapies to tumours using tumour-responsive nanomaterials is a promising area of cancer research with the potential to address the limitations of systemic administration such as on-target off-tumour toxicities and a lack of activity owing to the immunosuppressive tumour microenvironment (TME). Attempts to address these challenges include the design and functionalization of nanomaterials capable of releasing their cargoes in response to specific TME characteristics, thus facilitating the targeted delivery of immune-checkpoint inhibitors, cytokines, mRNAs, vaccines and, potentially, chimaeric antigen receptors as well as of agents that modulate the extracellular matrix and induce immunogenic cell death. In this Review, we describe these various research efforts in the context of the dynamic properties of the TME, such as pH, reductive conditions, reactive oxygen species, hypoxia, specific enzymes, high levels of ATP and locoregional aspects, which can be leveraged to enhance the specificity and efficacy of nanomaterial-based immunotherapies. Highlighting preclinical successes and ongoing clinical trials, we evaluate the current landscape and potential of these innovative approaches. We also consider future research directions as well as the most important barriers to successful clinical translation, emphasizing the transformative potential of tumour-responsive nanomaterials in overcoming the barriers that limit the activity of traditional immunotherapies, thus improving patient outcomes.
Indexed as
Identifiers
40050505What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.